Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 21, 2016

Alirocumab Provides Additional Reduction of 75% in Standardized Rate of Apheresis Treatment

European Heart Journal

 

Additional Info

European Heart Journal
Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipoprotein Apheresis: The ODYSSEY ESCAPE Trial
Eur Heart J 2016 Aug 29;[EPub Ahead of Print], PM Moriarty, KG Parhofer, SP Babirak, MA Cornier, PB Duell, B Hohenstein, J Leebmann, W Ramlow, V Schettler, V Simha, E Steinhagen-Thiessen, PD Thompson, A Vogt, B von Stritzky, Y Du, G Manvelian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading